Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | PDE3B | Q13370 | 16/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.58 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Siguazodan SCHEMBL12648714 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| Siguazodan SCHEMBL7744694 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| Siguazodan SCHEMBL1024118 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| Siguazodan SCHEMBL7744697 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| Siguazodan SCHEMBL17224472 | 0.83 | PDE3A (0.50) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL7746515 | 0.81 | PDE3B (0.56) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL7743969 | 0.81 | PDE3B (0.56) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| Siguazodan SCHEMBL4459608 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| Siguazodan SCHEMBL18522869 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| Siguazodan SCHEMBL1024119 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2023196821-A2 | TARGETING NEUROPOD CELL GUCY2C TO CONTROL VISCERAL PAIN AND APPETITE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2023055751-A1 | MIXED SOLVENT HYDROGEL SYSTEM FOR WOUND HEALING | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| EP-2704560-B1 | ORGAN CARE SOLUTION FOR EX-VIVO MACHINE PERFUSION OF DONOR LUNGS | TRANSMEDICS INC (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3943092-A2 | COMPOSITIONS FOR USE IN INDUCING DIFFERENTIATION OF HUMAN BROWN ADIPOCYTE PROGENITORS | Energesis Pharmaceuticals Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| EP-0961616-A4 | NON-HORMONAL METHOD OF CONTRACEPTION | TRUSTEES OF BOARD OF (US) | 2000-11-22 | — | — | EP | claimed |
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-1028690-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 2000-08-23 | — | — | EP | claimed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | claimed |
| EP-1012188-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN, Wolf-Georg, Prof. Dr. (DE) | 2000-06-28 | — | — | EP | claimed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| EP-0961616-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999020223-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 1999-04-29 | — | — | WO | claimed |
| WO-1999014239-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN WOLF GEORG (DE) | 1999-03-25 | — | — | WO | claimed |
| WO-1998010765-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1998-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | KDM4E 3388/4885ALDH1A1 2390/4885CYP1A2 3874/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | KDM4E 3388/4885ALDH1A1 2390/4885CYP1A2 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.